{"nctId":"NCT00524368","briefTitle":"A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)","startDateStruct":{"date":"2007-10"},"conditions":["Human Immunodeficiency Virus - Type 1"],"count":590,"armGroups":[{"label":"DRV/rtv 800/100 mg once daily","type":"EXPERIMENTAL","interventionNames":["Drug: Darunavir (DRV)","Drug: Ritonavir (rtv)"]},{"label":"DRV/rtv 600/100 mg twice daily","type":"EXPERIMENTAL","interventionNames":["Drug: Darunavir (DRV)","Drug: Ritonavir (rtv)"]}],"interventions":[{"name":"Darunavir (DRV)","otherNames":["TMC114"]},{"name":"Ritonavir (rtv)","otherNames":["rtv"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with documented human immunodeficiency virus - Type 1 (HIV-1) infection\n* Patients with a viral load greater than 1,000 HIV-1 ribonucleic acid (RNA) copies/mL\n* Stable highly active antiretroviral therapy (HAART) regimen for at least 12 weeks at screening\n* In the investigator's opinion, non-nucleoside reverse transcriptase inhibitors (NNRTIs) are not a valid treatment option, because of the patient's antiretroviral (ARV) treatment history, ARV resistance testing, medication-taking behavior, safety and tolerability concerns, or other patient-related factors\n* Prescreening or/and screening plasma HIV-1 RNA greater than 1,000 copies/mL on HAART regimen at screening\n\nExclusion Criteria:\n\n* Presence of any currently active conditions that fit the definition of the World Health Organization (WHO) Clinical Stage 4, with the following exceptions: stable cutaneous kaposi's sarcoma (ie, no internal organ involvement other than oral lesions) that is unlikely to require any form of systemic therapy during the study time period, wasting syndrome\n* Patients for whom an investigational ARV is part of the current regimen, with the following exceptions if applicable (depending on local regulatory approval): tenofovir, emtricitabine\n* Previous or current use of enfuvirtide (ENF), tipranavir and/or DRV\n* Life expectancy of less than 12 months\n* Pregnant or breast-feeding females\n* Any active clinically significant disease (eg, tuberculosis \\[TB\\], cardiac dysfunction, pancreatitis, acute viral infections) or findings during screening of medical history or physical examination that, in the investigator's opinion, would compromise the patient's safety or outcome of the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Virological Response at Week 48 (Number of Participants With Plasma Viral Load Less Than 50 Copies/mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm","description":"The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response. In all other cases, intermittent values were imputed with nonresponse. Resuppression after confirmed virologic failure was considered as failure in this algorithm.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"212","spread":null},{"groupId":"OG001","value":"210","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response at Week 48 (Viral Load Less Than 400 Copies/mL)","description":"Number of participants with confirmed plasma viral load less than 400 copies/mL at Week 48.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"226","spread":null},{"groupId":"OG001","value":"227","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in log10 Viral Load From Baseline at Week 48","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.23","spread":null},{"groupId":"OG001","value":"4.134","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.11","spread":null},{"groupId":"OG001","value":"-2.13","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Reach First Virologic Response","description":"Time (in weeks) to achieve viral load less than 50 copies/mL by the participants.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Loss of Virologic Response","description":"Time taken to lose the virologic response ie, plasma viral load less than 50 copies/mL by participants.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"250.235","spread":"6.598"},{"groupId":"OG001","value":"281.743","spread":"7.47"}]}]}]},{"type":"SECONDARY","title":"Time-averaged Difference (DAVG) of log10 Plasma Viral Load Over 48 Weeks","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.77","spread":"0.051"},{"groupId":"OG001","value":"-1.74","spread":"0.051"}]}]}]},{"type":"SECONDARY","title":"Change in CD4+ Cell Count From Baseline","description":"CD4+ cell count was calculated using the Last Observation Carried Forward (LOCF) algorithm.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"219","spread":null},{"groupId":"OG001","value":"236","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Functional Assessment of HIV Infection (FAHI) Score","description":"The FAHI is a 44-item questionnaire and incorporates 5 functional scales (physical well-being, emotional well-being/living with HIV, functional and global well-being, social well-being, and cognitive functioning). Each scale included several questions (all 5 scales include total 44 questions). For each question, participants gave a score of either 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit) and 4 (very much). Total FAHI imputed score is calculated by adding scores for each question. The range of total FAHI score is 0 to 176. Higher scores indicate worsening.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"123.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Adherent/Non-adherent to ARV as Determined by Modified Medication Adherence Self Report Inventory (M-MASRI) Questionnaire at Week 48","description":"Self-reported adherence to the ARV medications was measured. The M-MASRI asks participants to report the number of doses taken, as well as the number of doses taken during the last 30 days prior to the study visit by means of a horizontal visual analogue scale (VAS) that generates a self-rated percentage of doses of all the ARV medications taken during the past 30 days.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.4","spread":null},{"groupId":"OG001","value":"60.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.6","spread":null},{"groupId":"OG001","value":"39.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve From the Time of Study Medication Administration Upto 24 Hour Postdose (AUC24h) of DRV and Rtv","description":"Pharmacokinetic parameter AUC24h was assessed from the time of study medication administration upto 24 hour postdose. Population Pharmacokinetic Estimates of DRV and rtv were evaluated.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87788","spread":null},{"groupId":"OG001","value":"109401","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5776","spread":null},{"groupId":"OG001","value":"12588","spread":null}]}]}]},{"type":"SECONDARY","title":"Predose Plasma Concentration (C0h) of DRV and Rtv.","description":"Pharmacokinetic parameter C0h was assessed. Population Pharmacokinetic Estimates of DRV and rtv were evaluated.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1896","spread":null},{"groupId":"OG001","value":"3197","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"307","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Developing Mutations at Endpoint","description":"Development of Mutations in Virologic Failures (Plasma Viral Load less than 50 Copies/mL) at endpoint.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":294},"commonTop":["Diarrhoea","Nausea","Headache","Vomiting","Nasopharyngitis"]}}}